ImmuPharma PLC represents a values-driven corporate philosophy focused on innovation, scientific excellence, and delivering groundbreaking solutions to patients. The company is committed to enhancing human health through its cutting-edge research and development in the field of immunotherapy. ImmuPharma PLC places a strong emphasis on collaboration, fostering strategic partnerships with leading institutions and experts in the industry. With a steadfast commitment to patient well-being, ImmuPharma PLC strives to bring groundbreaking treatments to market, revolutionizing healthcare and improving quality of life.

ImmuPharma PLC is primarily present in various countries and regions worldwide. The company has a global presence, with key markets and operations in Europe, including the United Kingdom, France, and Switzerland. ImmuPharma also extends its reach to other areas, such as Asia, North America, and South America. Through strategic partnerships and collaborations, ImmuPharma aims to expand its market presence and ensure accessibility of its innovative healthcare solutions to a diverse range of patients and healthcare professionals internationally.

ImmuPharma PLC, a leading pharmaceutical company, has achieved several significant milestones. Firstly, the company successfully completed a Phase III clinical trial for its drug candidate, LupuzorTM, for the treatment of systemic lupus erythematosus (SLE). The trial showed promising results, demonstrating the drug's potential to address this debilitating autoimmune disease. Furthermore, ImmuPharma PLC secured a global licensing agreement with Avion Pharmaceuticals for the commercialization of LupuzorTM in the United States. This partnership ensures widespread access to this potentially life-changing treatment for SLE patients. ImmuPharma PLC's unwavering commitment to scientific innovation and partnership development has propelled it towards these remarkable achievements.

ImmuPharma PLC is a pharmaceutical company with a rich history and background. Founded in 1999, the company is focused on the development and commercialization of innovative therapeutics. ImmuPharma PLC has a diverse portfolio of drug candidates with a particular emphasis on autoimmune diseases and cancer. With extensive research and development capabilities, the company has made significant strides in advancing its drug candidates, including Lupuzor™ for lupus and Nucant for oncology. ImmuPharma PLC's commitment to scientific excellence and dedication to improving patient outcomes has positioned it as a leading player in the pharmaceutical industry.

The main competitors of ImmuPharma PLC in the market include companies like Roche Holding AG, AstraZeneca PLC, Novartis AG, and GlaxoSmithKline PLC. These pharmaceutical companies operate in similar therapeutic areas and have developed competing drugs or treatments targeting the same diseases or medical conditions as ImmuPharma.

ImmuPharma PLC is primarily active in the pharmaceutical industry.

The business model of ImmuPharma PLC is focused on developing and commercializing innovative drugs to treat serious medical conditions. The company's primary area of expertise lies in the field of autoimmune diseases and immune system disorders. ImmuPharma PLC aims to identify and advance biological compounds with the potential for improving patient outcomes and addressing unmet medical needs. By conducting research, clinical trials, and seeking regulatory approvals, ImmuPharma PLC strives to bring safe and effective therapeutic options to market, ultimately enhancing the quality of life for patients.

Коефициентът на цена спрямо печалбата (КЦП) на ImmuPharma е 0.

Коефициентът на цена към оборот (KUV) на ImmuPharma е 65,32.

AlleAktien качественият резултат за ImmuPharma е 2/10.

очаквана ImmuPharma оборотът е 99 474,00 GBP.

Печалбата за ImmuPharma в момента не може да бъде изчислена.

ImmuPharma PLC is a global biopharmaceutical company focused on developing therapeutics for the treatment of autoimmune diseases and cancer. It is headquartered in London, with subsidiaries in France and the USA. The company's business model is based on the identification, development, and commercialization of drugs made from peptides and proteins. It specializes in platform technologies that simplify the discovery and characterization of peptides and proteins. The company operates in multiple therapeutic areas, including the treatment of autoimmune diseases like lupus and multiple sclerosis. It has developed a drug called Lupuzor, currently in Phase III clinical trials and plans to market it in the USA and Europe once approved by regulatory authorities. In addition, ImmuPharma PLC is focused on cancer research and has developed a peptide called IPP-204106 that targets the CXCR4 receptor, which plays an important role in many types of cancer. The company is working on testing this peptide in clinical trials with patients who have advanced cancer. ImmuPharma PLC has also developed a platform technology called Ureka, which is specifically designed for the treatment of pain and inflammation. The company is currently working on several projects that utilize this technology, including peptides for the treatment of arthritis pain and chronic cough. In addition to developing its own products, ImmuPharma PLC collaborates with other companies to leverage their platform technologies and clinical expertise for the development of new treatments. It has partnerships with major pharmaceutical companies such as AstraZeneca and Ipsen to jointly develop new drugs. ImmuPharma PLC is listed on the London Stock Exchange and has a strong financial foundation. It has successfully completed multiple funding rounds and has a diversified investor base, including large institutional investors and private individuals. In summary, ImmuPharma PLC's business model is based on the development of innovative therapeutics for autoimmune diseases and cancer. The company specializes in platform technologies for the identification and characterization of peptides and proteins. It operates in multiple therapeutic areas and collaborates closely with other companies to develop new drugs. With its experience, expertise, and financial stability, ImmuPharma PLC is well positioned to continue its success.

ImmuPharma разпределя дивидента от 0 GBP на плащания годишно.

Дивидентата за ImmuPharma в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на ImmuPharma е GB0033711010.

WKN на ImmuPharma е A0BMC4.

Тикерът на ImmuPharma е IMM.L.

През последните 12 месеца ImmuPharma изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква ImmuPharma да изплати дивиденда в размер на 0 GBP.

Дивидентната доходност на ImmuPharma в момента е .

ImmuPharma изплаща дивидент на тримесечие. Той се разпределя в месеците .

ImmuPharma платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 GBP. Това съответства на дивидентна доходност от 0 %.

ImmuPharma се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от ImmuPharma на 30.09.2024 г. в размер на 0 GBP, трябваше да притежавате акцията в портфейла си преди Ex-деня на 30.09.2024 г..

Последното дивидентно плащане беше извършено на 30.09.2024 г..

През година 2023 ImmuPharma изплати 0 GBP под формата на дивиденти.

Дивидентите от ImmuPharma се изплащат в GBP.